Decriminalisation, legalisation, and medical access: what the terms mean

In public debates about psilocybin and other psychedelics, the words "decriminalisation", "legalisation", and "medical access" are often used as if they meant the same thing. They do not. Each describes a different policy model, answering a different question about what should be permitted, by whom, under what conditions, and how the state should respond to people who use these substances. Getting the vocabulary right matters: it helps people engage with reform proposals on their own terms rather than arguing past one another, and it makes it possible to compare what different countries — and different campaigns — are actually proposing.

Why the words matter

Drug policy bundles together several distinct decisions. Is a substance criminal to possess? May it be produced and sold lawfully? Is it approved as a medicine? How is it regulated at each stage, and by which authority? Conflating these questions creates confusion. A campaign to remove criminal penalties for personal possession is not the same as a campaign to permit commercial sales, and neither is identical to a proposal to make a substance available by prescription. Each model carries different legal, public-health, economic, and ethical implications — and different risks. Recognising the distinctions is the first step to evaluating any specific reform on its merits.

Decriminalisation

Decriminalisation typically means removing criminal penalties for personal possession of small quantities of a substance, while the substance itself remains legally prohibited. Production, supply, and sale usually remain criminal offences. Portugal's 2001 reform is the most cited example: personal possession of all drugs was reclassified as an administrative rather than a criminal matter, with health-focused referrals rather than prosecution. Decriminalisation does not create a legal market; it changes how the state responds to people who already use drugs.

Supporters of decriminalisation argue it reduces stigma, incarceration, and barriers to seeking help, and that it redirects resources from criminal justice toward health. A common criticism is that it does not address the harms of an unregulated supply: if possession is no longer criminal but production and sale remain so, the substance continues to reach users through illicit channels with no quality control. Decriminalisation is therefore often described as a harm-reduction measure rather than a full market reform.

Legalisation and regulation

Legalisation goes further: it permits the production, sale, and possession of a substance under a regulated framework. Canada's regulated cannabis market and Uruguay's earlier model are frequently cited examples outside psychedelics. Within psychedelics, Oregon's 2020 Measure 109 created a distinct legalised-and-regulated model for supervised psilocybin services, rather than a simple commercial market.

Legalisation raises questions that decriminalisation does not: who may produce, who may sell, to whom, at what potency, under what labelling, and how revenue is taxed. Supporters argue that regulation improves product safety, shrinks illicit markets, and generates tax revenue for public services. Critics worry about commercialisation, marketing to vulnerable groups, and the normalisation of use. The design of any legalised system — whether it resembles a tightly controlled pharmaceutical model or a more open consumer market — is usually more consequential than the label itself.

Medical access and rescheduling

Medical access refers to making a substance available as a prescription medicine, usually following regulatory review of evidence on safety, quality, and efficacy. In scheduling systems — including South Africa's, under the Medicines and Related Substances Act — substances are classified according to perceived risk and therapeutic value, with Schedule 7 reserved for substances considered to have the highest control needs and no accepted medical use. Rescheduling a substance to a lower schedule, or exempting it for specific medical uses, can permit prescription access while the substance remains otherwise prohibited.

Australia's 2023 decision by the Therapeutic Goods Administration (TGA) to reschedule psilocybin for defined treatment-resistant conditions is a leading example. Medical access is narrower than legalisation: it concerns clinical use under professional oversight, not recreational or general adult use. It also typically depends on a registered product, a prescribing pathway, and trained clinicians — meaning that rescheduling alone does not guarantee that patients can actually obtain the medicine.

How the models combine in practice

Real-world reforms often blend these models rather than choosing one in pure form. A jurisdiction might decriminalise personal possession, licence supervised use in dedicated facilities, and authorise prescription access separately — each strand addressing a different concern. South Africa currently sits at a restrictive point: psilocybin is listed under Schedule 7 of the Medicines Act, and possession outside any lawful authorisation can attract criminal penalties. The 2018 Constitutional Court judgment on cannabis privacy suggests, however, that South African courts are willing to interrogate whether criminalising personal use is proportionate — a precedent reformers often discuss, though its application to psilocybin remains untested.

Understanding the distinctions between these models helps clarify which question any given proposal is actually asking. Decriminalisation asks whether users should be criminals. Legalisation asks whether there should be a regulated market. Medical access asks whether a substance should be a medicine. These questions can be answered independently, and a coherent policy position on psilocybin needs to be clear about which one is being advanced.